AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10827161 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alfa alone (12‐month course with high initial doses) in group A (n=95)
Number of subjects: 307
Study 10827161 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alfa alone (10 MU for 3 months followed by 6 MU for 3 months, followed by 3 MU for 6 months) in group B (n=83)
Number of subjects: 307
Study 8853768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg b.d. plus antibiotics (amoxycillin, metronidazole, clarithromycin, cefuroxime axetil, tetracycline, tetracycline plus metronidazole, or clarithromycin plus tetracycline) for 14 days
Number of subjects: 100
Study 1477191 — intervention group
Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 6
Study 6505888 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled physical exercise in reduced environmental lighting (54 lux)
Number of subjects: 0
Study 6505888 — intervention group
Group type: COMPARATOR
Intervention: Controlled physical exercise in normal lighting (320 lux)
Number of subjects: 0
Study 6505888 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled physical exercise
Number of subjects: 0
Study 6505888 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled exercise (step-climbing) for 30 minutes
Number of subjects: 0
Study 30675515 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus nonsteroidal aromatase inhibitor (AI)
Number of subjects: 493
Study 30675515 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal aromatase inhibitor (AI)
Number of subjects: 493
Study 30675515 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus nonsteroidal AI
Number of subjects: 493
Study 30675515 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal AI
Number of subjects: 493
Study 30675515 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 493
Study 30675515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 29121545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 41
Study 29121545 — intervention group
Group type: COMPARATOR
Intervention: Wait-Listed Control (WLC)
Number of subjects: 41
Study 29121545 — intervention group
Group type: COMPARATOR
Intervention: Exercise-Training Active Control (AC)
Number of subjects: 41
Study 27578807 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 300
Study 27578807 — intervention group
Group type: COMPARATOR
Intervention: TAP stenting
Number of subjects: 300
Study 24603217 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose statin (atorvastatin 10 mg/d or equivalent, n=675)
Number of subjects: 1355
Study 24603217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dose statin (atorvastatin 20 or 40 mg/d or equivalent, n=680)
Number of subjects: 1355
Study 24603217 — intervention group
Group type: COMPARATOR
Intervention: Moderate dose statin
Number of subjects: 1355
Study 24603217 — intervention group
Group type: COMPARATOR
Intervention: Intensive dose statin
Number of subjects: 1355
Study 24603217 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1355
Study 22066819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (40 g, cocoa > 85%)
Number of subjects: 40
Study 22066819 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (cocoa < 35%)
Number of subjects: 40
Study 22066819 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin (0.1-10 μm)
Number of subjects: 40
Study 19808926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Interactive Diary (DID)
Number of subjects: 130
Study 19808926 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 130
Study 17296645 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 10
Study 17296645 — intervention group
Group type: COMPARATOR
Intervention: CPET
Number of subjects: 10
Study 16139183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 146
Study 16139183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 12126459 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg once daily without rifampicin (group A)
Number of subjects: 24
Study 12126459 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 800 mg once daily with rifampicin (group A-2)
Number of subjects: 24
Study 12126459 — intervention group
Group type: COMPARATOR
Intervention: rifampicin in bodyweight‐adjusted fixed‐dose combination (group B)
Number of subjects: 24
Study 10428251 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered tampon before physician-directed swabs of the cervix
Number of subjects: 93
Study 10428251 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed swab testing before using the self-administered tampon
Number of subjects: 93
Study 7595108 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy (SMT) applied by experienced physicians
Number of subjects: 30
Study 7595108 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation therapy (SMT) applied by novice manipulators
Number of subjects: 30
Study 2197004 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg.kg‐1 intramuscular codeine
Number of subjects: 30
Study 2197004 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg.kg‐1 of ten per cent aerosol lidocaine
Number of subjects: 30
Study 7196885 — intervention group
Group type: COMPARATOR
Intervention: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group I, half received levamisole, half received placebo)
Number of subjects: 2
Study 7196885 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group II, all received levamisole)
Number of subjects: 2
Study 30365412 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL using conventional 3 mW/cm UVA irradiation for 30 minutes
Number of subjects: 40
Study 30365412 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL using accelerated 9 mW/cm UVA irradiation for 10 minutes
Number of subjects: 40
Study 29616621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype disinfectant spray (0.13% w/v benzalkonium chloride and a cooling agent)
Number of subjects: 0
Study 29616621 — intervention group
Group type: COMPARATOR
Intervention: BACTROBAN® disinfectant spray
Number of subjects: 0
Study 29616621 — intervention group
Group type: COMPARATOR
Intervention: Negative control (0.9% w/v saline)
Number of subjects: 0
Study 29616621 — intervention group
Group type: COMPARATOR
Intervention: Positive control (70% w/v isopropyl alcohol, pilot study only)
Number of subjects: 0
Study 26492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of interactive information via Wechat along with standard education (n = 387)
Number of subjects: 770
Study 26492848 — intervention group
Group type: COMPARATOR
Intervention: Standard education (controls, n = 383)
Number of subjects: 770
Study 24500060 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 53
Study 24500060 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 53
Study 22089205 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL 7.2% NaCl/6% hydroxyethyl starch (HT group)
Number of subjects: 24
Study 22089205 — intervention group
Group type: COMPARATOR
Intervention: 500 mL 6% hydroxyethyl starch (IT group)
Number of subjects: 24
Study 19737845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce weight loss (Look AHEAD)
Number of subjects: 15496
Study 19737845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension (ACCORD)
Number of subjects: 15496
Study 19737845 — intervention group
Group type: COMPARATOR
Intervention: Joint eligibility for both trials
Number of subjects: 15496
Study 17892406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Glasgow Outcome Scale (GOS) assessment
Number of subjects: 66
Study 17892406 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face Glasgow Outcome Scale (GOS) assessment
Number of subjects: 66
Study 16896964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 295
Study 16896964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 11990442 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 14
Study 11990442 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein Derivative (EMD)
Number of subjects: 14
Study 9449871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg three times daily for 7 days
Number of subjects: 40
Study 9449871 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 7 days
Number of subjects: 40
Study 7664854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized saline (hypertonic saline 3%)
Number of subjects: 39
Study 7664854 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 39
Study 7664854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizers (De Vilbiss Ultraneb 99 and Fisoneb)
Number of subjects: 39
Study 7664854 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (Pari LL with Master Compressor)
Number of subjects: 39
Study 7664854 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 39
Study 7664854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7664854 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline concentrations (3%, 4%, 5%)
Number of subjects: 39
Study 2651509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 10 mg twice daily (b.i.d.)
Number of subjects: 37
Study 2651509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 10 mg b.i.d. and two puffs (400 micrograms) of budesonide, b.i.d.
Number of subjects: 37
Study 2651509 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs (400 micrograms) of budesonide, b.i.d.
Number of subjects: 37
Study 1093481 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate (2.0%) cream
Number of subjects: 99
Study 1093481 — intervention group
Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 99
Study 30428907 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention at a local fitness center with a paid membership
Number of subjects: 76
Study 30428907 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 76
Study 28939567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital administration of 180 mg ticagrelor
Number of subjects: 1862
Study 28939567 — intervention group
Group type: COMPARATOR
Intervention: In-hospital administration of 180 mg ticagrelor
Number of subjects: 1862
Study 25448245 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based telerehabilitation program
Number of subjects: 30
Study 25448245 — intervention group
Group type: COMPARATOR
Intervention: In-clinic program (control)
Number of subjects: 30
Study 23864112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention grounded in activation principles
Number of subjects: 587
Study 23864112 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 587
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Optimal glycemic control (A1C <6.1%)
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Good glycemic control (A1C 6.1-6.9%)
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Moderate glycemic control (A1C 7.0-7.9%)
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Poor glycemic control (A1C ≥8.0%)
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: A1C values ≥ 6.1% at 26 weeks' gestation
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: A1C values ≥ 7.0% at 34 weeks' gestation
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Each 1% decrement in A1C before pregnancy
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at first antenatal visit
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at 26 weeks' gestation
Number of subjects: 749
Study 21636798 — intervention group
Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at 34 weeks' gestation
Number of subjects: 749
Study 17397949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg p.o.)
Number of subjects: 6
Study 17397949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17063129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 250
Study 17063129 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 250
Study 12807346 — intervention group
Group type: EXPERIMENTAL
Intervention: D-camphor
Number of subjects: 0
Study 12807346 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract from fresh crataegus berries
Number of subjects: 0
Study 12807346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of D-camphor and extract from fresh crataegus berries (CCC)
Number of subjects: 0
Study 12807346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11277825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3086
Study 11277825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086
Study 9551417 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (on-line conductivity ultrafiltrate kinetic modeling)
Number of subjects: 39
Study 9551417 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (standard treatment with fixed dialysate conductivity)
Number of subjects: 39
Study 8177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing interventions (physical, psychological, and social aspects of care)
Number of subjects: 1
Study 3288866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral IgA-IgG (73% IgA and 26% IgG)
Number of subjects: 434
Study 3288866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral IgA-IgG)
Number of subjects: 434
Study 4888873 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium bromide (Cetiprin)
Number of subjects: 0
Study 4888873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31531547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium tissue
Number of subjects: 29
Study 31531547 — intervention group
Group type: COMPARATOR
Intervention: Normal conjunctival tissue
Number of subjects: 29
Study 31209851 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5) for 48 weeks
Number of subjects: 45
Study 31209851 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for 24 weeks followed by A0.3/BPO2.5 for 24 weeks
Number of subjects: 45
Study 28438596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg)
Number of subjects: 32
Study 28438596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25896108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 32
Study 25896108 — intervention group
Group type: EXPERIMENTAL
Intervention: USP
Number of subjects: 32
Study 25896108 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-OCT
Number of subjects: 32
Study 25896108 — intervention group
Group type: COMPARATOR
Intervention: Control (non-surgery eye)
Number of subjects: 32
Study 25896108 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery corneas
Number of subjects: 32
Study 23376998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study 23376998 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 36
Study 23376998 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 36
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in managing hypertension (HT)
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in managing CKD with hypertension (HT+CKD)
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in managing CKD, hypertension, and diabetes (CKD+HT+DM)
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of pay-for-performance indicators (P4P) in patients with hypertension
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with hypertension
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of P4P in patients with HT and CKD
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with HT and CKD
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of P4P in patients with HT, CKD, and DM
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with HT, CKD, and DM
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in managing proteinuria in CKD
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of BP treatment thresholds in CKD
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of BP treatment thresholds when proteinuria is factored in
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence levels based on gender and age
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of P4P targets in patients treated with angiotensin modulating drugs
Number of subjects: 201
Study 21819552 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of P4P targets in patients with CKD
Number of subjects: 201
Study 19939894 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4(+) tumors
Number of subjects: 823
Study 19939894 — intervention group
Group type: COMPARATOR
Intervention: CXCR4(‐) tumors
Number of subjects: 823
Study 16483360 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical atlantoaxial fixation
Number of subjects: 250
Study 16483360 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 250
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg i.v. once daily (n=72)
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice a day (n=71)
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g every 6 hours (n=69)
Number of subjects: 287
Study 15143910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 287
Study 15143910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 15143910 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 287
Study 11784339 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtxA) 1000 IU
Number of subjects: 59
Study 11784339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9257757 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (350 mg of levofloxacin hemihydrate)
Number of subjects: 16
Study 9257757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30087196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation manual for home use
Number of subjects: 50
Study 30087196 — intervention group
Group type: COMPARATOR
Intervention: Verbal recommendations (control group)
Number of subjects: 50
Study 27918189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based therapy for parental conflict (Parenting Together)
Number of subjects: 30
Study 27918189 — intervention group
Group type: COMPARATOR
Intervention: Parents' Group (psycho-educational intervention based on Separated Parents Information Program)
Number of subjects: 30
Study 25250291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dapsone gel plus oral isotretinoin 20 mg daily
Number of subjects: 58
Study 25250291 — intervention group
Group type: COMPARATOR
Intervention: Oral isotretinoin 20 mg daily (Control group with vehicle gel)
Number of subjects: 58
Study 23297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized electric acupuncture and massage
Number of subjects: 120
Study 23297553 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 120
Study 20411833 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling (500 cycles at 5 ‐ 55 degrees C; dwell time of 30 seconds; transfer time of 10 seconds)
Number of subjects: 20
Study 20411833 — intervention group
Group type: COMPARATOR
Intervention: No thermocycling (control group)
Number of subjects: 20
Study 20411833 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling
Number of subjects: 20
Study 16882819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (2 mg via metered dose inhaler in the emergency department plus 500 microg twice daily via Diskus for 10 doses after discharge)
Number of subjects: 69
Study 16882819 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg in the emergency department plus 5 daily doses of 1 mg/kg after discharge)
Number of subjects: 69
Study 15600377 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Number of subjects: 0
Study 15600377 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0